Oligomerix Receives $3.19 Million NIH Commercialization Readiness Pilot Grant for Alzheimer's Disease Therapy

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s disease (AD) and related neurodegenerative disorders, today announced that the company was awarded a $3.19 million grant from the National Institute on Aging (NIA) at National Institutes of Health (NIH). The three-year SBIR/STTR Commercialization Readiness Pilot (CRP) Program award will enable the company to further develop its small molecule tau self-association inhibitor.

NIH’s goal with this funding program is to help companies with previously funded SBIR/STTR Phase II/IIB projects transition to the commercialization stage by providing additional support for late-stage research R D and product development activities.

“We have generated compelling preclinical evidence that inhibiting tau self-association can significantly reduce pathological downstream insoluble tau aggregate formation which could lead to altering disease progression in tauopathies including AD,” said James Moe, Ph.D., MBA, President and CEO of Oligomerix. “As we move closer to IND submission and Phase 1 clinical testing, this generous funding support from the NIH will enable us to focus on later stage development work and commercialization planning activities for our lead candidate,” Dr. Moe added.

Most clinical studies for AD have focused on amyloid beta but have had limited success in patients. There continues to be mounting evidence that tau pathology drives neurodegeneration in diseases like AD, frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP). However, clinical-stage programs targeting tau are currently focused on intervention after tau proteins have aggregated. Oligomerix’s novel approach targets tau self-association, the initial step before tau aggregate formation.

About Oligomerix’s Lead Program

Oligomerix’s lead candidate is a small molecule inhibitor of tau self-association and targets the beginning of the tau aggregation cascade. The activity of the drug translated from in vitro and cell assays to animal studies, validating the company’s screening approach. In vivo proof-of-concept studies demonstrated compound efficacy in two transgenic mouse models with tau pathology representative of AD and frontotemporal dementia. In a study recently published in the Journal of Alzheimer’s Disease, Oligomerix and the Feinstein Institutes for Medical Research at Northwell Health, reported that the compound inhibited hippocampal self-associated tau in the htau mouse model of tauopathy which expresses the six CNS isoforms of the human tau protein. Initial preclinical safety studies show the drug is well tolerated with no adverse events or behavioral abnormalities observed. The compound is being developed with an accompanying novel biomarker.

About Oligomerix, Inc.

Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for Alzheimer’s disease and related dementias by targeting tau self-association. The company’s drug discovery platform has identified a pipeline of novel small molecule inhibitors, with preclinical IND-enabling studies in progress for the lead program. Oligomerix’s small molecule approach blocks the formation of all tau aggregates by targeting tau self-association, known as the beginning of the aggregation cascade, whereas other companies have focused on targeting large tau aggregates formed downstream. The NYC-based company is located at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.

Oligomerix is seeking strategic partners to support the acceleration and advancement of these important programs. For more information about Oligomerix, please visit http://www.oligomerix.com.

DISCLAIMER

Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Number R44AG053150. “The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

Contacts Company Contacts Jack Pasini Chief Commercial Officer 917-912-4088 jpasini@oligomerix.com

James Moe, Ph.D., MBA President and CEO 212-568-0365 jmoe@oligomerix.com

Media Contact Michelle Linn Bioscribe 774-696-3803 michelle@bioscribe.com